Draft guidance consultation
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about empagliflozin
Marketing authorisation indication
2.1 Empagliflozin (Jardiance, Boehringer Ingelheim) is indicated in adults for 'the treatment of symptomatic chronic heart failure'.
2.2 Empagliflozin is recommended for treating chronic heart failure with reduced ejection fraction in adults (NICE technology appraisal guidance 773).
Dosage in the marketing authorisation
2.3 The dosage schedule is available in the summary of product characteristics for empagliflozin.
Price
2.4 The list price of 10 mg empagliflozin is £36.59 per 28-tablet pack (excluding VAT; BNF online accessed January 2023). The annual treatment cost is £477.30.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Document
Question on Document
Question on Document
Question on Document